Press Releases

Media Inquiries - media@caredxinc.com

Date	Title and Summary	Additional Formats
Toggle Summary Jun 15, 2020	CareDx Announces Closing of Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif. , June 15, 2020 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today	View HTML
Toggle Summary Jun 10, 2020	CareDx Announces Pricing of Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif. , June 10, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today	View HTML
Toggle Summary Jun 09, 2020	CareDx Announces Proposed Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif. , June 09, 2020 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today	View HTML
Toggle Summary Jun 08, 2020	CareDx Announces 2020 Annual Meeting of Stockholders to be Held as a Virtual Meeting SOUTH SAN FRANCISCO, Calif. , June 08, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today	View HTML
Toggle Summary Jun 04, 2020	CareDx to Participate at the Goldman Sachs Global Healthcare Conference SOUTH SAN FRANCISCO, Calif. , June 04, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today	View HTML
Toggle Summary May 28, 2020	CareDx to Present at the Jefferies Virtual Healthcare Conference SOUTH SAN FRANCISCO, Calif. , May 28, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today	View HTML
Toggle Summary May 27, 2020	CareDx Presents the Latest AlloSure Data in Virtual Meetings Leading transplant clinicians to present ten abstracts accepted for presentation at the American Transplant Congress SOUTH SAN FRANCISCO, Calif. , May 27, 2020 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and	View HTML
Toggle Summary May 15, 2020	CareDx's AlloSeq Tx 17 Awarded CE Mark Approval CE Mark approval enables global availability of innovative Hybrid-Capture Technology HLA testing for transplant patients SOUTH SAN FRANCISCO, Calif. , May 15, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and	View HTML
Toggle Summary May 14, 2020	CareDx and Veracyte Announce Exclusive Partnership for Transplant Rejection Testing on nCounter System SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 14, 2020-- CareDx, Inc . (Nasdaq: CDNA) and Veracyte, Inc . (Nasdaq: VCYT) today announced an agreement through which CareDx will become the exclusive worldwide commercialization partner for solid organ transplant-rejection tests on the nCounter®	View HTML
Toggle Summary May 07, 2020	CareDx Brings the Transplant Patient Community Together David Ayres joins a panel co-hosted by CareDx and National Kidney Foundation to talk about the impact of COVID-19 on the transplant community SOUTH SAN FRANCISCO, Calif. , May 07, 2020 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery,	View HTML